Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Subfoveal Choroidal Neovascularization CNV Secondary to Wet Age-related Macular Degeneration AMD”

14 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 14 of 14 results

Testing effectiveness (Phase 2)Study completedNCT00138632
What this trial is testing

Safety and Efficacy of Oral PTK787 in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)

Who this might be right for
Wet Age-Related Macular Degeneration
Novartis 50
Large-scale testing (Phase 3)Study completedNCT03844074
What this trial is testing

A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)

Who this might be right for
Age-related Macular DegenerationNeovascular Age-related Macular DegenerationWet Macular Degeneration
Outlook Therapeutics, Inc. 61
Large-scale testing (Phase 3)Study completedNCT00826371
What this trial is testing

Evaluation of Safety and Efficacy of Once Monthly Ranibizumab Injections in Chinese Patients With Wet Age Related Macular Degeneration (AMD) Patients

Who this might be right for
Age Related Macular Degeneration
Novartis Pharmaceuticals 114
Large-scale testing (Phase 3)Study completedNCT04597632
What this trial is testing

An Extension Study Assessing the Efficacy and Safety of Brolucizumab in a Treat-to-Control Regimen in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2303 (TALON) Study

Who this might be right for
Neovascular Age-related Macular Degeneration
Novartis Pharmaceuticals 248
Post-approval studies (Phase 4)Study completedNCT01972789
What this trial is testing

Comparison of Treatment Regimens Using Ranibizumab: Intensive (Resolution of Intra- and Sub-retinal Fluid) vs Relaxed (Resolution of Intra-retinal Fluid and/or Sub-retinal Fluid >200µm at the Foveal Centre)

Who this might be right for
Subfoveal Choroidal Neovascularization CNV Secondary to Wet Age-related Macular Degeneration AMD
Novartis Pharmaceuticals 349
Testing effectiveness (Phase 2)Ended earlyNCT02228304
What this trial is testing

Study of the Intravitreal Implantation of NT-503-3 Encapsulated Cell Technology (ECT) for the Treatment of Recurrent Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)

Who this might be right for
Macular Degeneration
Neurotech Pharmaceuticals 42
Post-approval studies (Phase 4)Study completedNCT04679935
What this trial is testing

Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens in Neovascular Age-related Macular Degeneration

Who this might be right for
Age-related Macular Degeneration
Novartis Pharmaceuticals 52
Post-approval studies (Phase 4)Study completedNCT05269966
What this trial is testing

Study to Evaluate the Safety and Effectiveness of Intravitreal Injections (IVI) of Brolucizumab in Patients With Neovascular Age-related Macular Degeneration (nAMD)

Who this might be right for
Neovascular Age-related Macular Degeneration (nAMD)
Novartis Pharmaceuticals 105
Large-scale testing (Phase 3)Study completedNCT03834753
What this trial is testing

A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)

Who this might be right for
Age-related Macular DegenerationNeovascular Age-related Macular DegenerationWet Macular Degeneration
Outlook Therapeutics, Inc. 228
Large-scale testing (Phase 3)Study completedNCT04005352
What this trial is testing

Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)

Who this might be right for
Age-related Macular Degeneration
Novartis Pharmaceuticals 734
Testing effectiveness (Phase 2)Study completedNCT00239928
What this trial is testing

Clinical Study Of Pegaptanib Sodium (EYE001) For Wet-Type Age-Related Macular Degeneration

Who this might be right for
Macular Degeneration
Pfizer 61
Large-scale testing (Phase 3)Study completedNCT00150202
What this trial is testing

Clinical Study Of EYE001 For Wet-Type AMD (Age-Related Macular Degeneration)

Who this might be right for
Macular Degeneration
Pfizer 90
Early research (Phase 1)Study completedNCT00503022
What this trial is testing

Safety and Tolerability of an Intravenous Infusion of ACZ885 in Patients With Wet Age-Related Macular Degeneration

Who this might be right for
Wet Age-Related Macular Degeneration
Novartis 20
Large-scale testing (Phase 3)Study completedNCT00090623
What this trial is testing

RhuFab V2 (Ranibizumab) in Subjects With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)

Who this might be right for
Macular Degeneration
Genentech, Inc. 180